Kidney patients needed to test how drug moves in body

NCT ID NCT07426380

Recruiting now Knowledge-focused Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how the drug eloralintide enters the bloodstream and leaves the body in people with severe kidney disease or kidney failure, compared to healthy volunteers. About 28 participants will receive a single shot under the skin. The study lasts about 14 weeks and does not aim to treat any condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome end stage renal failure impaired renal function disease kidney disorder kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

END-STAGE KIDNEY DISEASE KIDNEY DISEASE KIDNEY FAILURE, CHRONIC RENAL IMPAIRMENT RENAL INSUFFICIENCY RENAL INSUFFICIENCY, CHRONIC

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Floridian Clinical Research, LLC
RECRUITING

Miami Lakes, Florida, 33016-1518, United States

Contact Phone: •••-•••-••••

Contact
Omega Research Orlando LLC
RECRUITING

Orlando, Florida, 32808, United States

Contact Phone: •••-•••-••••

Contact